Experienced biotech people found new company and aim for phase I next year

The people behind Action Pharma and Synact have founded another biotech company to develop a new inflammation drug. The team has appointed Symphogen-founder Kirsten Drejer as chairman of the board and plans to initiate clinical trials already next year.

Lone Veng, CEO in Resother Pharma. | Foto: Resother Pharma

A new actor has entered the Danish biotech industry. Recently founded Resother Pharma has ambitious plans to make it to the very top with an experimental, innovative inflammation drug - and an experienced team is ready for the task.

"We have geared our organization, development plan and budget to show a positive phase II result, and we aim to achieve this within five years," says Lone Veng, CEO in Resother Pharma. She previously conducted research for Lundbeck and MSD and had different leadership positions in Leo Pharma and Clinical-Microbiomics.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch


Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier